Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1)

Biomaterials

Volumn 34, Issue 28, 2013, Pages 6882-6892

  Zeng, San ^a   Xiong, May P ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Animals; Combination therapy; Micelles; Rapamycin; SiRNA; YB 1

Indexed keywords

COMBINATION THERAPY; HUMAN PROSTATE CANCER; POLYMERIC MICELLE; RAPAMYCIN; SIRNA; THERAPEUTIC EFFICACY; TRIBLOCK POLYMERS; YB-1;

AMINO ACIDS; ANIMALS; ASSOCIATION REACTIONS; BIOCOMPATIBILITY; BIOSYNTHESIS; CELL CULTURE; GENE THERAPY; POLYETHYLENE GLYCOLS; POLYMERS; PROTEINS;

MICELLES;

BINDING PROTEIN; RAPAMYCIN; SMALL INTERFERING RNA TARGETING Y BOX BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; GENETIC TRANSFECTION; MALE; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DRUG CARRIERS; HUMANS; MALE; MICE; MICE, NUDE; MICELLES; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SIROLIMUS; Y-BOX-BINDING PROTEIN 1;

ANIMALIA; MUS MUSCULUS;

EID: 84879463482     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.05.010     Document Type: Article

References (58)

1. Vézina C., Kudelski A., Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. JAntibiot (Tokyo) 1975, 28:721-726.
2. Buck E., Eyzaguirre A., Brown E., Petti F., McCormack S., Haley J.D., et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006, 5:2676-2684.
3. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
4. Ji J., Zheng P.S. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol 2010, 117:103-108.
5. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6:729-734.
6. Gulhati P., Cai Q., Li J., Liu J., Rychahou P.G., Qiu S., et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 2009, 15:7207-7216.
7. van der Poel H.G., Hanrahan C., Zhong H., Simons J.W. Rapamycin induces smad activity in prostate cancer cell lines. Urol Res 2003, 30:380-386.
8. Noh W.C., Mondesire W.H., Peng J.Y., Jian W.G., Zhang H.X., Dong J.J., et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004, 10:1013-1023.
9. Guba M., Koehl G.E., Neppl E., Doenecke A., Steinbauer M., Schlitt H.J., et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 2005, 18:89-94.
10. Seeliger H., Guba M., Kleespies A., Jauch K.-W., Bruns C.J. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007, 26:611-621.
11. Raught B., Gingras A.C., Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A 2001, 98:7037-7044.
12. Wanner K., Hipp S., Oelsner M., Ringshausen I., Bogner C., Peschel C., et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006, 134:475-484.
13. Kroemer G., Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005, 5:886-897.
14. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
15. Simamora P., Alvarez J.M., Yalkowsky S.H. Solubilization of rapamycin. Int J Pharm 2001, 213:25-29.
16. Napoli K.L., Wang M.E., Stepkowski S.M., Kahan B.D. Distribution of sirolimus in rat tissue. Clin Biochem 1997, 30:135-142.
17. Forrest M.L., Won C.Y., Malick A.W., Kwon G.S. Invitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. JControl Release 2006, 110:370-377.
18. Law J.H., Li Y., To K., Wang M., Astanehe A., Lambie K., et al. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS One 2010, 5:e12661.
19. Eliseeva I.A., Kim E.R., Guryanov S.G., Ovchinnikov L.P., Lyabin D.N. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Moscow) 2011, 76:1402-1433.
20. Skabkin M.A., Evdokimova V., Thomas A.A.M., Ovchinnikov L.P. The major messenger ribonucleoprotein particle protein p50 (YB-1) promotes nucleic acid strand annealing. JBiol Chem 2001, 276:44841-44847.
21. Lyabin D.N., Eliseeva I.A., Ovchinnikov L.P. YB-1 synthesis is regulated by mTOR signaling pathway. PLoS One 2012, 7:e52527.
22. Evdokimova V., Tognon C., Ng T., Ruzanov P., Melnyk N., Fink D., et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009, 15:402-415.
23. Lovett D.H., Cheng S., Cape L., Pollock A.S., Mertens P.R. YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem Biophys Res Commun 2010, 398:482-488.
24. Wu Y., Yamada S., Izumi H., Li Z., Shimajiri S., Wang K.Y., et al. Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. JSurg Oncol 2012, 105:724-730.
25. Knosel T., Emde A., Schluns K., Chen Y., Jurchott K., Krause M., et al. Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia 2005, 7:741-747.
26. Bargou R.C., Jurchott K., Wagener C., Bergmann S., Metzner S., Bommert K., et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997, 3:447-450.
27. Ohga T., Koike K., Ono M., Makino Y., Itagaki Y., Tanimoto M., et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996, 56:4224-4228.
28. Kuwano M., Oda Y., Izumi H., Yang S.J., Uchiumi T., Iwamoto Y., et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004, 3:1485-1492.
29. Yang J.Y., Ha S.-A., Yang Y.-S., Kim J.W. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer 2010, 10:388.
30. Lee C., Dhillon J., Wang M.Y., Gao Y., Hu K., Park E., et al. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 2008, 68:8661-8666.
31. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
32. Zhang L., Radovic-Moreno A.F., Alexis F., Gu F.X., Basto P.A., Bagalkot V., et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2007, 2:1268-1271.
33. Bae Y., Fukushima S., Harada A., Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Ed Engl 2003, 42:4640-4643.
34. Kakizawa Y., Furukawa S., Kataoka K. Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. JControl Release 2004, 97:345-356.
35. Xiong M.P., Forrest M.L., Ton G., Zhao A., Davies N.M., Kwon G.S. Poly(aspartate-g-PEI800), a polyethylenimine analogue of low toxicity and high transfection efficiency for gene delivery. Biomaterials 2007, 28:4889-4900.
36. Lu Y., Chau M., Boyle A.J., Liu P., Niehoff A., Weinrich D., et al. Effect of pendant group structure on the hydrolytic stability of polyaspartamide polymers under physiological conditions. Biomacromolecules 2012, 13:1296-1306.
37. Gary D.J., Puri N., Won Y.-Y. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. JControl Release 2007, 121:64-73.
38. Woodward S.C., Brewer P.S., Moatamed F., Schindler A., Pitt C.G. The intracellular degradation of poly(epsilon-caprolactone). JBiomed Mater Res 1985, 19:437-444.
39. Raffetseder U., Frye B., Rauen T., Jurchott K., Royer H.D., Jansen P.L., et al. Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection. JBiol Chem 2003, 278:18241-18248.
40. Miyata K., Oba M., Nakanishi M., Fukushima S., Yamasaki Y., Koyama H., et al. Polyplexes from poly(aspartamide) bearing 1,2-diaminoethane side chains induce pH-selective, endosomal membrane destabilization with amplified transfection and negligible cytotoxicity. JAm Chem Soc 2008, 130:16287-16294.
41. Kanayama N., Fukushima S., Nishiyama N., Itaka K., Jang W.-D., Miyata K., et al. APEG-based biocompatible block catiomer with high buffering capacity for the construction of polyplex micelles showing efficient gene transfer toward primary cells. ChemMedChem 2006, 1:439-444.
42. Masago K., Itaka K., Nishiyama N., Chung U.-i., Kataoka K. Gene delivery with biocompatible cationic polymer: pharmacogenomic analysis on cell bioactivity. Biomaterials 2007, 28:5169-5175.
43. De Smedt S.C., Demeester J., Hennink W.E. Cationic polymer based gene delivery systems. Pharm Res 2000, 17:113-126.
44. Wang Y., Gao S., Ye W.-H., Yoon H.S., Yang Y.-Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
45. Alshamsan A., Haddadi A., Incani V., Samuel J., Lavasanifar A., Uludag H. Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol Pharm 2009, 6:121-133.
46. Kim W.J., Christensen L.V., Jo S., Yockman J.W., Jeong J.H., Kim Y.-H., et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 2006, 14:343-350.
47. Kim H.J., Ishii A., Miyata K., Lee Y., Wu S., Oba M., et al. Introduction of stearoyl moieties into a biocompatible cationic polyaspartamide derivative, PAsp(DET), with endosomal escaping function for enhanced siRNA-mediated gene knockdown. JControl Release 2010, 145:141-148.
48. Klampfer L. Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 2006, 6:107-121.
49. Alvarez J.V., Greulich H., Sellers W.R., Meyerson M., Frank D.A. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006, 66:3162-3168.
50. Morgensztern D., McLeod H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005, 16:797-803.
51. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008, 11:32-50.
52. Hsieh A.C., Liu Y., Edlind M.P., Ingolia N.T., Janes M.R., Sher A., et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485:55-61.
53. Thoreen C.C., Chantranupong L., Keys H.R., Wang T., Gray N.S., Sabatini D.M. Aunifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012, 485:109-113.
54. Zhang Y., Zhang J.W., Lv G.Y., Xie S.L., Wang G.Y. Effects of STAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells. Int J Med Sci 2012, 9:216-224.
55. Bevins R.L., Zimmer S.G. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res 2005, 65:6957-6966.
56. Sato T., Suzuki M., Sato Y., Echigo S., Rikiishi H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 2006, 28:1233-1241.
57. Dalla Pozza E., Lerda C., Costanzo C., Donadelli M., Dando I., Zoratti E., et al. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Biochim Biophys Acta 2013, 1828:1396-1404.
58. Caso J., Masko E.M., Ii J.A.T., Poulton S.H., Dewhirst M., Pizzo S.V., et al. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate 2013, 73:449-454.